---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-010478"
form_type: "8-K"
ticker: "GKOS"
cik: "0001192448"
company_name: "GLAUKOS Corp"
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:16:45.917938+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Glaukos reports record Q2 sales $95.7M (+19% YoY), raises FY2024 guidance

## Summary
- Record net sales of $95.7M, up 19% reported / 20% constant currency YoY.
- Glaucoma segment sales $75.9M (+23% YoY); Corneal Health $19.8M (+7% YoY).
- GAAP net loss $53.9M ($1.06 loss per share) vs $32.8M ($0.68) in Q2 2023.
- Non-GAAP net loss $26.3M ($0.52 loss per share) improved from $26.6M ($0.55) prior year.
- FY2024 net sales guidance raised to $370M–$376M from $357M–$365M.

## SEC filing metadata
- accession: 0001558370-24-010478
- form_type: 8-K
- ticker: GKOS
- cik: 0001192448
- company_name: GLAUKOS Corp
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1192448/000155837024010478/0001558370-24-010478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1192448/000155837024010478/gkos-20240731x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-010478
- JSON: https://secwatch.observer/filing/0001558370-24-010478.json
- Plain text: https://secwatch.observer/filing/0001558370-24-010478.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.